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ABSTRACT 
Purpose: To evaluate factors associated with radiation-induced bronchiolitis obliterans organizing 
pneumonia (BOOP) syndrome after breast-conserving therapy. 
Methods and Materials: We retrospectively analyzed 702 women patients with breast cancer who 
received radiation therapy after breast-conserving surgery at 7 institutions between July 1995 and 
December 2006. In all patients, the whole breast was irradiated with 2 tangential photon beams. 
The criteria used for the diagnosis of radiation-induced BOOP syndrome were as follows: (1) 
radiation therapy to the breast within 12 months; (2) general and/or respiratory symptoms lasting 
for at least 2 weeks; (3) radiographs showing lung infiltrations outside the radiation port; and (4) no 
evidence of a specific cause. 
Results: Radiation-induced BOOP syndrome was seen in 16 patients (2.3%). Eleven patients 
(68.8%) were administered steroids. The duration of steroid administration ranged from 1 week to 
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3.7 years (median, 1.1 years). Multivariate analysis revealed that age (≧50years; odds ratio [OR], 
8.88; 95% confidence interval [95% CI], 1.16–67.76; p = 0.04) and concurrent endocrine therapy 
(OR, 3.05; 95% CI, 1.09–8.54; p = 0.03) were significantly associated with BOOP syndrome. Of 
the 161 patients whose age was 50 years and older and who received concurrent endocrine therapy, 
10 (6.2%) developed BOOP syndrome.  
Conclusions: Age (≧50years) and concurrent endocrine therapy can promote the development of 
radiation-induced BOOP syndrome after breast-conserving therapy. The physicians should 
carefully follow up patients who received breast-conserving therapy, especially those who are older 
than 50 years and received concurrent endocrine therapy during radiation therapy. 
 
KEY WORDS 
Breast cancer, Breast-conserving surgery, Radiation therapy, Radiation-induced BOOP syndrome, 
Endocrine therapy 
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INTRODUCTION 
Breast-conserving therapy (BCT) has become the standard of care for early-stage breast cancer. 
Postoperative radiation therapy significantly reduces the local recurrence rate. The recent update of 
the EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) meta-analysis revealed that 
higher local control rate translated into an improved survival in patients receiving radiation therapy 
as part of their BCT (1). 
Bronchiolitis obliterans organizing pneumonia (BOOP) syndrome is known as lung injury 
occurring after radiation therapy to the breast. It is characterized by lung infiltrates outside the 
radiation port (2–4). Radiation-induced BOOP syndrome is different from radiation pneumonitis 
(RP). RP tends to occur shortly after the completion of radiation therapy (5) and is generally 
limited to the irradiated field; further, migration of shadows is not observed in RP (6). 
Radiation-induced BOOP syndrome after BCT is rare (3, 4), but steroids are often administered 
over a prolonged period, and their side effects lead to complications (2–4). 
To date, only 2 small studies have analyzed the factors associated with radiation-induced BOOP 
syndrome after BCT (3, 4); the analysis, however, could not identify any factor. Therefore, we 
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retrospectively analyzed 702 female patients with breast cancer who had undergone BCT, and 
attempted to analyze the factors associated with radiation-induced BOOP syndrome after BCT.  
 
METHODS AND MATERIALS 
Study design 
 Between July 1995 and December 2006, 1074 consecutive patients with breast cancer received 
radiation therapy after breast-conserving surgery at 7 institutions*. Of the 1074 patients, 702 
patients met the following criteria and were thus eligible for this study: (1) radiation therapy was 
accomplished; (2) radiation therapy was planned by a full-time radiation oncologist; and (3) the 
follow-up period from radiation therapy was more than 12 months. The medical records, radiation 
therapy documentation, and portal or simulation images of the 702 patients were examined. Chest 
roentgenograms were obtained for patients with respiratory or somatic symptoms. If an abnormal 
shadow was detected on the chest roentgenogram, computed tomography (CT) scanning was 
performed. 
  The observation period ranged from 12.0 to 128.0 months (median, 34.0 months). 
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  The characteristics of the 702 eligible patients are shown in Table 1. All patients were women. 
Data on smoking habits were incomplete. 
  The details of radiation therapy are shown in Table 2. In all patients, the whole breast was 
irradiated with 2 tangential photon beams. For the treatment of the supraclavicular region, an 
anterior photon beam was used. For the boost irradiation to tumor bed, an electron beam was used. 
  The details of the adjuvant therapy administered are shown in Table 3. The regimen that was 
administered for more than 1 month and for the longest period of time ranging from 1 year before 
to 1 year after radiation therapy was selected in the items of chemotherapy and endocrine therapy. 
The regimen that was administered for more than 1 month and for the longest period of time during 
radiation therapy was selected in the items of concurrent chemotherapy and concurrent endocrine 
therapy. 
  The diagnosis of radiation-induced BOOP syndrome was based on the criteria proposed by 
Crestani et al. (4): (1) radiation therapy to the breast within 12 months; (2) general and/or 
respiratory symptoms lasting for at least 2 weeks; (3) radiographic lung infiltrations outside the 
radiation port; and (4) no evidence of a specific cause. 
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Statistical analyses 
Factors associated with radiation-induced BOOP syndrome were analyzed by logistic regression. 
Age (<50 or ≧50 years), the side affected, asthma, diabetes, drug allergy, chemotherapy, 
concurrent chemotherapy, endocrine therapy, concurrent endocrine therapy, concurrent endocrine 
therapy without chemotherapy and trastuzumab, concurrent endocrine therapy with chemotherapy 
before radiation therapy, endocrine therapy after radiation therapy, radiation therapy method, 
photon energy (4–6 MV or 10 MV), wedge filter, central lung distance (<3 or ≧3 cm), field length 
(<20 or ≧20 cm), irradiation to the supraclavicular region, boost to tumor bed, and overall 
radiation therapy time (<36 or ≧36 days) were evaluated as categorical data. The odds ratios (OR) 
and their 95% confidence intervals (95% CI) were also estimated. Values of p less than 0.05 were 
considered significant. Data processing and statistics were carried out using SPSS software, version 
11.0 (SPSS, Chicago, IL).  
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RESULTS 
Incidence of BOOP syndrome 
Sixteen patients developed BOOP syndrome (Table 4). The incidence of BOOP syndrome was 
2.3%.  
  Their age ranged from 44 to 74 years (median, 60 years). Five had right breast cancer and 11 had 
left breast cancer. Of the 16 patients, no patients had collagen vascular disease, 1 had asthma, 1 had 
diabetes, and 1 had drug allergy. For whole-breast irradiation, 14 patients received 50 Gy in 25 
fractions; 1 patient, 50 Gy in 20 fractions; and 1 patient, 48 Gy in 24 fractions. The photon energy 
was 4 MV in 11 patients, 6 MV in 4 patients, and 10 MV in 1 patient. The radiation methods were 
the opposed pair method in 9 patients, the nonopposed pair method in 4 patients, and the half-beam 
method in 3 patients. A wedge filter was used in 14 patients. The central lung distance ranged from 
1.3 to 3.6 cm (median, 2.1 cm); the field length, from 15 to 21 cm (median, 18 cm). No patients 
underwent irradiation to the supraclavicular region. One patient underwent boost irradiation to 
tumor bed. Overall radiation therapy time was from 33 to 47 days (median, 36.5 days). Four 
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patients received chemotherapy. Fifteen patients received endocrine therapy, and 10 patients 
received endocrine therapy concurrent with radiation therapy. No patients received trastuzumab. 
 
Clinical courses of patients with BOOP syndrome 
The interval from the completion of radiation therapy to occurrence of any symptoms ranged 
from 2.3 to 7.9 months (median, 3.8 months). The clinical symptoms in the 16 patients were cough 
(16 patients), fever (7 patients), sputum (5 patients), and dyspnea (3 patients). In 10 patients, 
abnormal pulmonary findings were observed in the unilateral diseased area; in 6 patients, in the 
bilateral diseased area. Eleven patients (68.8%) were administered steroids. The duration of steroid 
administration ranged from 1 week to 3.7 years (median, 1.1 years). In 2 patients with a longer 
duration of steroid administration, cataract developed as a side effect. All the 16 patients improved, 
but relapses occurred in 8 patients. Finally, these 8 patients also improved, and steroids were not 
administered to any patients at the time of this study. 
 
Univariate analysis of factors associated with BOOP syndrome 
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Table 5 shows the results of the univariate analysis for the effect of various factors on the 
incidence of BOOP syndrome. Age (≧50 years; OR, 9.04; 95% CI, 1.19–68.87; p = 0.03) and 
concurrent endocrine therapy (OR, 3.12; 95% CI, 1.12–8.68; p = 0.03) were significantly 
associated with BOOP syndrome. The association between concurrent endocrine therapy without 
chemotherapy or trastuzumab and BOOP syndrome was borderline significant (OR, 2.24; 95% CI, 
0.89–6.64; p = 0.08). Of 161 patients whose age was 50 years and older and who received 
concurrent endocrine therapy, 10 (6.2%) developed BOOP syndrome. 
 
Multivariate analysis of factors associated with BOOP syndrome 
  We performed multivariate analysis to analyze factors that were found to be significantly 
associated with BOOP syndrome in the univariate analysis. Table 6 shows the results of the 
multivariate analysis for the effect of factors on the incidence of BOOP syndrome. In multivariate 
analysis, as in univariate analysis, age (≧50 years; OR, 8.88; 95% CI, 1.16–67.76; p = 0.04) and 
concurrent endocrine therapy (OR, 3.05; 95% CI, 1.09–8.54; p = 0.03) were significantly 
associated with BOOP syndrome. 
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DISCUSSION 
BOOP was reported for the first time in 1985 by Epler et al. Cough, flu-like symptoms, or 
dyspnea is observed. Clinically, radiographs show an unusual pattern of patchy consolidations with 
ground-glass opacities. Histologic characteristics include polypoid masses of granulation tissue in 
the lumens of small airways, alveolar ducts, and some alveoli (7). Most cases of BOOP are 
idiopathic, but the histologic reaction pattern of BOOP can be seen in association with connective 
tissue disease, drugs, infection, and aspiration (8). BOOP also occurs after radiation therapy, and 
radiation-induced BOOP syndrome is different from radiation pneumonitis (RP). RP usually occurs 
within 3 months after the completion of radiation therapy (5), but radiation-induced BOOP 
syndrome often occurs after more than 4 months (2–4, 9), as was the case in our study. In 
radiation-induced BOOP syndrome, shadows extend beyond the radiation port and often migrate 
(2–4, 9). Although in RP, shadows occasionally extend beyond the radiation port, these are less 
marked than those within the radiation port (6). RP is a direct effect of irradiation, but 
radiation-induced BOOP syndrome has been suggested to be an indirect effect of irradiation, that is, 
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autoimmune processes play important roles in its development (3, 5, 10, 11). 
The incidence of radiation-induced BOOP syndrome after BCT was reported to be 2.5% (3) and 
2.4% (4). It was 2.3% in our study, which is similar to that reported previously. 
Dramatic improvement is achieved by administration of corticosteroids in radiation-induced 
BOOP syndrome, but relapses often occur while tapering the dose or after suspending the treatment. 
Therefore, steroids are administered over a prolonged period, and their side effects lead to 
complications (2–4). In our study, of the 16 patients, 11 (68.8%) were administered steroids, and 
the duration of the steroid administration ranged from 1 week to 3.7 years (median, 1.1 years). Two 
patients who were administered steroids for longer durations developed cataract as a side effect. 
Only 2 reports have analyzed the factors associated with radiation-induced BOOP syndrome 
after BCT (3, 4). Although no factors associated with radiation-induced BOOP syndrome were 
found in those reports, the number of patients was small, with 157 cases (3) and 206 cases (4). 
Further, radiation therapy factors, such as the central lung distance and field length, were not 
analyzed, with the exception of the total dose (3). We performed this study based on the hypothesis 
that radiation therapy factors as well as patient characteristics and adjuvant therapy might be 
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associated with radiation-induced BOOP syndrome. Therefore, when we analyzed 702 cases, 
concurrent endocrine therapy and age (≧50 years) were found to be significantly associated with 
radiation-induced BOOP syndrome. Although the association between concurrent endocrine 
therapy without chemotherapy and trastuzumab and radiation-induced BOOP syndrome was only 
borderline significant (p = 0.08), this result may be because the number of patients who received 
this type of therapy was small (n = 173). 
 In our study, of the 16 patients who developed BOOP syndrome, 10 received endocrine therapy 
concurrently with radiation therapy: 4 received tamoxifen, 4 received anastrozole, and 2 received 
toremifene. In some studies, tamoxifen was significantly associated with lung fibrosis or 
pulmonary changes in radiography after radiation therapy to the breast (12–14). Colletta et al. 
reported that toremifene induced human fetal lung fibroblasts to secrete transforming growth factor 
beta (TGF-beta) (15), which has been implicated in the pathogenesis of pulmonary fibrosis (16). 
These previous findings may be related with the result in our study. However, in other studies, 
tamoxifen was not found to be associated with pneumonitis or pulmonary changes observed in the 
radiograph after administering radiation therapy to the breast (17, 18).  
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  Age was significantly associated with RP after radiation therapy to the breast in many studies 
(12, 13, 19–21). It was reported that patients whose age is 50 years and older (13) and 58 years and 
older (12) are at a higher risk for developing RP. 
  In some studies, chemotherapy (17, 22, 23), central lung distance (23, 24), and irradiation to the 
supraclavicular region (17, 20, 22) were significantly associated with RP after radiation therapy to 
the breast. In our study, these factors were not associated with radiation-induced BOOP syndrome. 
The result demonstrated that the central lung distance, field length, and irradiation to the 
supraclavicular region were not associated with radiation-induced BOOP syndrome. This supports 
the notion that radiation-induced BOOP syndrome is not a direct effect of irradiation. 
  This study had certain limitations. It was retrospectively designed, and the number of subjects 
with BOOP syndrome was only 16. It is necessary to perform a large-scale prospective study. 
 
CONCLUSIONS 
Age (≧ 50 years) and concurrent endocrine therapy can promote the development of 
radiation-induced BOOP syndrome after breast-conserving therapy. The physicians should 
                                                                   Katayama 
 
16 
16 
carefully follow up patients who received breast-conserving therapy, especially those who are older 
than 50 years and received concurrent endocrine therapy during radiation therapy. 
Table 1. Patient characteristics  (n = 702)
Characteristics
Age (years) 26-85 (median 54)
Side  right/left/bilateral 340/355/7
Collagen vascular disease  Yes/No 1*/701
Asthma  Yes/No 21/681
Diabetes  Yes/No 38/664
Drug allergy  Yes/No 70/632
Clinical stage (UICC)
  0 30
  Ⅰ 383
  ⅡA 197
  ⅡB 60
  ⅢA 18
  ⅢB 6
  ⅢC 5
  Ⅳ 3
Histologic type
  Non-invasive ductal carcinoma 30
  Invasive ductal carcinoma 618
  Others 54
* Chronic articular rheumatism
Table 2. Radiation therapy details
Characteristics
Whole breast irradiation 
  Dose and fractions
    46 Gy in 23 fractions 1
    48 Gy in 24 fractions 1
    48.4 Gy in 22 fractions 1
    50 Gy in 25 fractions 693
    50 Gy in 20 fractions 2
    50.4 Gy in 28 fractions 1
    52 Gy in 26 fractions 2
    60 Gy in 30 fractions 1
  Photon energy  4 MV/6 MV/10 MV 414/190/98
  Method  Opposed pair/Nonopposed pair/Half-beam 325/306/71
  Wedge filter  Yes/No 515/187
  Central lung distance (cm) 0.1–4.9 (median 1.9)
  Field length (cm) 13–26 (median 18)
Irradiation to the supraclavicular region  Yes/No 12/690
Boost to tumor bed  Yes/No 76/626
  Dose and fractions
    6 Gy in 2 fractions 1
    9 Gy in 3 fractions 1
    10 Gy in 5 fractions 74
  Electron energy (MeV) 6–18 (median 10)
  Area (cm2) 19.6–112 (median  50) 
Overall radiation therapy time (days) 29–88 (median 36)
Table 3. Adjuvant therapy details
Characteristics
Chemotherapy    Yes/No 247/455
  Anthracycline-based regimens 78
  Taxane-based regimens 59
  CMF 59
  Others 51
Concurrent chemotherapy  Yes/No 22/680
  CMF 10
  Doxifluridine 5
  Others 7
Endocrine therapy  Yes/No 542/160
  Tamoxifen 278
  Anastrozole 174
  Toremifene 31
  Others 59
Concurrent endocrine therapy  Yes/No249/453
  Tamoxifen 152
  Anastrozole 66
  Toremifene 13
  Others 18
Trastuzumab  Yes/No 10/692
Abbreviations: CMF = cyclophosphamide, methotrexate, 5-fluorouracil
Table 4. Clinical characteristics of 16 patients with BOOP syndrome
No. Age
Drug
before RT
Drug
concurrent
with RT
Drug
after RT CLD
Field
length
Period
before onset,
after RT
Location of
pulmonary
findings
Duration of
steroid
administration
1 51 years Tamoxifen Tamoxifen Tamoxifen 2.0 cm 20 cm 2.3 months Unilateral 1.1 years
2 65 years ― Anastrozole Anastrozole 2.9 cm 18 cm 2.5 months Bilateral 3.7 years
3 74 years CMF ― ― 1.6 cm 17 cm 3.4 months Bilateral ―
4 60 years ― Tamoxifen Tamoxifen, 1.8 cm 15 cm 3.4 months Unilateral 4.6 months
5 60 years ― ― Anastrozole 2.5 cm 17 cm 3.4 months Unilateral 1.7 years
6 58 years ― Anastrozole Anastrozole 2.1 cm 18 cm 3.6 months Bilateral 1.2 years
7 67 years Anthracycline ― Anastrozole 1.8 cm 18 cm 3.6 months Unilateral 1.1 years
8 58 years ― Toremifene Toremifene 3.6 cm 19 cm 3.8 months Unilateral ―
9 57 years ― Tamoxifen Tamoxifen 2.1 cm 19 cm 3.8 months Bilateral ―
10 68 years ― Anastrozole Anastrozole 1.3 cm 19 cm 4.6 months Bilateral ―
11 44 years ― ― Tamoxifen 2.2 cm 17 cm 4.8 months Unilateral ―
12 50 years ― ― Tamoxifen 2.6 cm 19 cm 4.8 months Unilateral 3 weeks
13 61 years ― ― Tamoxifen 2.1 cm 20 cm 5.3 months Unilateral 1 week
14 52 years Tamoxifen Tamoxifen Tamoxifen 2.0 cm 16 cm 6.8 months Unilateral 11 months
15 64 years Anastrozole, taxane Anastrozole Anastrozole 1.6 cm 18 cm 7.1 months Unilateral 1 month
16 60 years ― Toremifene Toremifene 2.1 cm 21 cm 7.9 months Bilateral 3.2 years
Abbreviations: RT = radiation therapy; CLD = central lung distance; CMF = cyclophosphamide, methotrexate, 5-fluorouracil
taxane = taxane-based regimens; anthracycline = anthracycline-based regimens
Table 5. Univariate analysis of factors associated with BOOP syndrome
Parameters BOOP n = 16 No BOOP n = 686 OR 95% CI p
Age: ≧50 years 15 (94%) 428 (62%) 9.04 1.19–68.87 0.03
Side: left 11 (69%) 344 (50%) 2.14 0.74–6.23 0.16
Asthma 1 (6%) 20 (3%) 2.22 0.28–17.64 0.45
Diabetes 1 (6%) 37 (5%) 1.17 0.15–9.10 0.88
Drug allergy 1 (6%) 69 (10%) 0.60 0.08–4.58 0.62
Chemotherapy 5 (31%) 242 (35%) 0.83 0.29–2.43 0.74
Concurrent chemotherapy 0 (0%) 22 (3%) 0 ― 0.98
Endocrine therapy 15 (94%) 527 (77%) 4.53 0.59–34.53 0.15
Concurrent endocrine therapy 10 (63%) 239 (35%) 3.12 1.12–8.68 0.03
Concurrent endocrine therapy without chemotherapy and trastuzumab 7 (44%) 166 (24%) 2.44 0.89–6.64 0.08
Concurrent endocrine therapy with chemotherapy before RT 1 (6%) 32 (5%) 1.36 0.17–10.64 0.77
Endocrine therapy after RT 15 (94%) 522 (76%) 4.71 0.62–35.96 0.13
OPM vs. (NOPM or HBM) 9 (56%) 316 (46%) 1.51 0.55–4.09 0.42
Energy of photon : 4-6-MV 15 (94%) 589 (86%) 2.47 0.32–18.92 0.38
Wedge filter 14 (88%) 472 (73%) 2.59 0.58–11.48 0.21
Central lung distance: ≧3cm 1 (6%) 33 (5%) 1.32 0.17–10.29 0.79
Field length: ≧20cm 3 (19%) 204 (30%) 0.55 0.15–1.93 0.35
Irradiation to the supraclavicular region 0 (0%) 12 (2%) 0 ― 0.98
Boost to tumor bed 1 (6%) 75 (11%) 0.54 0.07–4.17 0.56
Overall RT time: ≧36days 13 (81%) 523 (76%) 1.35 0.38–4.80 0.64
Abbreviations: OR = odds ratio; CI = confidence interval; vs. = versus; RT = radiation therapy;
OPM = opposed pair method; NOPM = nonopposed pair method; HBM = half-beam method
Table 6. Multivariate analysis of factors associated with BOOP syndrome
Parameters OR 95% CI p
Age : ≧50years 8.88 1.16–67.76 0.04
Concurrent endocrine therapy 3.05 1.09–8.54 0.03
Abbreviations: OR = odds ratio; CI = confidence interval
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